Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Assertio"

3 News Found

Zydus’s acquisition of Assertio to bolster its specialty pharma presence in US market
News | June 20, 2026

Zydus’s acquisition of Assertio to bolster its specialty pharma presence in US market

Upon completion of the merger, Assertio will become a wholly owned subsidiary of Zydus Lifesciences and will be delisted from the Nasdaq

Novartis AG wins case against four domestic pharma firms
News | November 03, 2021

Novartis AG wins case against four domestic pharma firms

The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech

Biocon launches Everolimus tablets in the US
Drug Approval | October 04, 2021

Biocon launches Everolimus tablets in the US

According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Zydus’s acquisition of Assertio to bolster its specialty pharma presence in US market

Alembic Pharma receives USFDA tentative approval for Binimetinib tablets

Manipal Hospitals Mukundapur launches advanced Neuro Biplane Cathlab

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation

Packaging